Updated Jul 16, 2026
Palasis Maria has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $20K.
Maria Palasis is the President and CEO of Beta Bionics, Inc., a medical device company focused on improving diabetes management through innovative technology. She has also held the position of President and CEO at Lyra Therapeutics, Inc.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-26 | BBNX | Beta Bionics, Inc. | A — Grant or award | 17.0K | $0.00 | |
| 2026-04-03 | LYRA | Lyra Therapeutics, Inc. | D — Derivative transaction | 2.0K | $0.00 | |
| 2026-01-15 | BBNX | Beta Bionics, Inc. | A — Grant or award | 4.0K | $0.00 | |
| 2026-01-08 | LYRA | Lyra Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.7K | $3.36 | $6K |
| 2025-07-10 | LYRA | Lyra Therapeutics, Inc. | S — Open-market sale | 1.6K | $8.91 | $14K |
| 2024-10-18 | LYRA | Lyra Therapeutics, Inc. | A — Grant or award | 300.0K | $0.00 |
Maria Palasis is the President and CEO of Beta Bionics, Inc., a medical device company focused on improving diabetes management through innovative technology. She has also held the position of President and CEO at Lyra Therapeutics, Inc.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($20K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Palasis Maria profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.